HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study

Francis Kiweewa[1]*, **Allahna Esber**[2,3]◉, **Ezra Musingye**[1]◉, **Domonique Reed**[2,3], **Trevor A. Crowell**[2,3], **Fatim Cham**[3], **Michael Semwogerere**[1], **Rosemary Namagembe**[1], **Alice Nambuya**[1], **Cate Kafeero**[1], **Allan Tindikahwa**[1], **Leigh Anne Eller**[2,3], **Monica Millard**[2], **Huub C. Gelderblom**[4], **Babajide Keshinro**[5], **Yakubu Adamu**[5], **Jonah Maswai**[6], **John Owuoth**[7], **Valentine Chepkorir Sing'oei**[6], **Lucas Maganga**[8], **Emmanuel Bahemana**[9], **Samoel Khamadi**[9], **Merlin L. Robb**[2,3], **Julie A. Ake**[2], **Christina S. Polyak**[2,3‡], **Hannah Kibuuka**[1‡]

1 Makerere University- Walter Reed Project, Kampala, Uganda, 2 U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America, 3 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, United States of America, 4 International AIDS Vaccine Initiative, New York, New York, United States of America, 5 HJF Medical Research International, Abuja, Nigeria, 6 HJF Medical Research International, Kericho, Kenya, 7 HJF Medical Research International, Kisumu, Kenya, 8 Mbeya Medical Research Centre, Mbeya, Tanzania, 9 HJF Medical Research International, Mbeya, Tanzania

◉ These authors contributed equally to this work.
‡ CP and HK are joint senior authors on this work.
* fkiweewa@muwrp.org

Abstract

Introduction

The 2016 WHO consolidated guidelines on the use of antiretroviral drugs defines HIV virologic failure for low and middle income countries (LMIC) as plasma HIV-RNA $\geq$ 1000 copies/mL. We evaluated virologic failure and predictors in four African countries.

Materials and methods

We included HIV-infected participants on a WHO recommended antiretroviral therapy (ART) regimen and enrolled in the African Cohort Study between January 2013 and October 2017. Studied outcomes were virologic failure (plasma HIV-RNA $\geq$ 1000 copies/mL at the most recent visit), viraemia (plasma HIV-RNA $\geq$ 50 copies/mL at the most recent visit); and persistent viraemia (plasma HIV-RNA $\geq$ 50 copies/mL at two consecutive visits). Generalized linear models were used to estimate relative risks with their 95% confidence intervals.

Results

2054 participants were included in this analysis. Viraemia, persistent viraemia and virologic failure were observed in 396 (19.3%), 160 (7.8%) and 184 (9%) participants respectively. Of the participants with persistent viraemia, only 57.5% (92/160) had confirmed virologic failure. In the multivariate analysis, attending clinical care site other than the Uganda sitebeing

on 2nd line ART (aRR 1.8, 95% CI 1·28–2·66); other ART combinations not first line and not second line (aRR 3.8, 95% CI 1.18–11.9), a history of fever in the past week (aRR 3.7, 95% CI 1.69–8.05), low CD4 count (aRR 6.9, 95% CI 4.7–10.2) and missing any day of ART (aRR 1·8, 95% CI 1·27–2.57) increased the risk of virologic failure. Being on 2nd line therapy, the site where one receives care and CD4 count < 500 predicted viraemia, persistent viraemia and virologic failure.

Conclusion

In conclusion, these findings demonstrate that HIV-infected patients established on ART for more than six months in the African setting frequently experienced viraemia while continuing to be on ART. The findings also show that being on second line, low CD4 count, missing any day of ART and history of fever in the past week remain important predictors of virologic failure that should trigger intensified adherence counselling especially in the absence of reliable or readily available viral load monitoring. Finally, clinical care sites are different calling for further analyses to elucidate on the unique features of these sites.

Introduction

The goal of antiretroviral therapy (ART) for HIV infection is to achieve and maintain virologic suppression, thereby preventing disease progression and transmission. In 2014, the Joint United Nations Programme on HIV/AIDS (UNAIDS) set the 90-90-90 global targets for elimination of HIV, whereby the third 90 represents a target to achieve viral suppression in at least 90% of patients initiating ART by 2020 [1], Abrams and Strasser [2]. The 2016 WHO consolidated antiretroviral guidelines define virologic suppression for a public health approach as HIV RNA < 1000 copies/mL [3]. By the end of 2016, at least 19 million people living with HIV globally had initiated ART [4]. Of these, 72% were living in sub-Saharan Africa [5]. The public health impact of this achievement will depend on the extent to which those initiating ART are able to achieve and maintain virologic suppression [6].

Progress towards the 90-90-90 targets in Sub-Saharan Africa is hampered by reports from the region that viraemia and virologic failure are common (11% to 24%), with 71% to 90% of the latter having HIV drug resistance mutations [7–11]. Identifying factors contributing to viraemia and virologic failure is key to achieving this target.

Previously published research findings highlight a number of factors that may be associated with viraemia, including WHO stage, clinician skill level, age, CD4 count, treatment history, and suboptimal adherence [12–15]. However, many of the studies on the factors associated with viraemia are in high income countries that use a lower threshold to determine viraemia [16]. In contrast, studies from the majority of low and middle income countries use the WHO public health approach based thresholds for determining viraemia [17]. Additionally, some of the published studies on HIV viral suppression or viraemia have been limited by small sample size [18, 19]. The relative role of various factors associated with viraemia may also be dependent on the ART program setting and the local context. Therefore, a comparison of viraemia and predictors across different contexts, and a comparison of the different definitions is key to informing adjustments in program level strategies. We evaluated the prevalence of virologic failure, viraemia and the associated factors among adult male and female HIV-infected participants in four African countries.

Materials and methods

Study design and participants

The African Cohort Study (AFRICOS) is a prospective, multicenter cohort study following HIV-infected participants aged 18 years and older attending outpatient clinical care facilities supported by the U.S. Military HIV Research Program (MHRP) through the U.S. President's Emergency Fund for AIDS Relief (PEPFAR) in East Africa and Nigeria (Fig 1). A detailed description of the AFRICOS objectives, methodology and procedures can be found in the AFRICOS protocol (https://www.hivresearch.org/sites/default/files/RV%20329%20Protocol%20v2.6%2021NOV2016%20%28clean%29.pdf) and has previously been described [20]. In brief, participants are evaluated at baseline and biannually thereafter. At each visit, participants were administered a medical history and physical exam, completed a broad demographic and behavioural questionnaire, extracted ART treatment history and other clinical outcomes from the medical records, and underwent phlebotomy. ART was started at provider discretion based on local guidelines in place at time of care.

Laboratory assessment

Laboratory assessment at each visit included CD4 T-cell count, plasma HIV viral load, full heamogram, serum chemistry, serum cryptococcal antigen, and QuantiFERON for TB exposure. HIV RNA viral load was assessed every 6 months using several different platforms; Roche

Modified from *yourfreetemplates.com*

Fig 1. The African Cohort Study (AFRICOS) clinical sites.

https://doi.org/10.1371/journal.pone.0211344.g001

Cobas Ampliprep/Cobas TaqMan HIV-1 Test, v2.0 (linear range 20–10,0000,000 copies/mL), Roche High Pure/COBAS TaqMan HIV-1 Test v2·0 (linear range 34–10,000,000 copies/mL), Roche COBAS AmpliPrep/COBAS TaqMan 48 HIV-1 Test (linear range 48–10,000,000 copies/mL) or Abbott Real Time HIV-1 Viral Load assay (linear range 40–10,000,000 copies/mL). Adherence was assessed by self-report.

Data collection and outcomes

Data were entered and verified into the ClinPlus Data Management system (DZS Software Solutions, Bound Brock, NJ). Participants' data were eligible for inclusion in the analysis if they had been continuously taking ART for at least six months and had viral load data at the most recent visit. The 6 months cut off was informed by evidence that the majority of patients achieve viral suppression within 3–6 months of initiating ART [21–23] and the WHO recommendation to check for viral suppression after at least 6 months of treatment. The primary outcome was virologic failure, defined as plasma HIV RNA $\geq$ 1000 copies/mL at the most recent visit. As secondary outcomes we examined viraemia (HIV RNA >50 copies/mL) and persistent viraemia, defined as plasma HIV RNA $\geq$50 copies/mL at the two most recent visits six months apart. Exploratory variables considered in the analysis included gender, age, study enrollment sites, education, employment, and marital status. Body mass index (BMI) was categorized as low (<18·5kg/m^2), normal (18·5 kg/m^2–24·9 kg/m^2) or high ($\geq$25 kg/m^2). Current CD4 count was categorized as <500 vs $\geq$500 cells/mm^3. Other exploratory variables considered included duration on ART (0·5–2 years, 2–5 years, $\geq$5 years), history of fever in the past week (Yes vs No), adherence (zero days of ART missed vs at least one day of ART missed in the past month), ART regimen type (1st line as efavirenz/nevirapine based regimens vs 2nd line as lopinavir-ritonavir/atazanavir-ritonavir based regimens), drug or alcohol use (no drugs or <3 drinks per day vs. drug use or $\geq$3 drinks per day).

Statistical analysis

Participants were dichotomized as those with and without virologic failure at their most recent visit. Characteristics were compared across the two groups using chi-squared testing for categorical variables and Kruskall-Wallis test for continuous variables. Generalized linear models with a robust standard error and Poisson distribution were used to estimate unadjusted, site-adjusted, and fully adjusted relative risks (RRs) and 95% confidence intervals (CIs) for associations between factors of interest and virologic failure. Backwards selection with 0.05 significance level was used to select variables for inclusion in the final multivariable models. We repeated the analyses examining our two secondary outcomes, viraemia and persistent viraemia. All analyses were performed using Stata 14·0 (StataCorp, College Station, Texas).

Ethics

The study was approved by institutional review boards of the Walter Reed Army Institute of Research, Makerere University School of Public Health, Kenya Medical Research Institute, Tanzania National Institute of Medical Research, and Nigerian Ministry of Defence. Each participant provided informed consent that was documented with a signature or fingerprint if illiterate.

Role of the funding source

This work was primarily funded by PEPFAR. The funding source had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The authors

Fig 2. Flow diagram of AFRICOS participants included in the current analysis.

had full access to all the data related to this analysis and independently made the decision to submit the findings for publication.

Results

Between January 2013 and October 2017, 2678 HIV-infected participants enrolled in AFRICOS. Of these, 2577 (96·2%) had viral load data for the most recent visit. After excluding 523 participants on ART for less than six months, 2054 HIV-infected participants were included in the final analysis (Fig 2).

Demographic and clinical characteristics

Participants were enrolled from sites at the South Rift Valley-Kenya (n = 820, 39·9%), Kisumu-Kenya (n = 365, 17·8%), Uganda (n = 352, 17·1%), Tanzania (n = 307, 14·9%) and Nigeria (n = 210, 10·2%). Most participants were female (57·4%), aged 40 years or older

(60·5%), married or cohabiting (59·4%), and had some form of employment (59·2%). Overall, 4·1% of all participants reported a history of illicit drug use or consumption of ≥ 3 drinks of alcohol per day. The majority of participants (89·2%) were on 1st line therapy; and 73% had been on ART for at least 2 years (Table 1).

Of the 2054 eligible participants, 184 (9%) had virologic failure at the most recent visit, varying by study site with a low of 3.4% (12/352) at the Uganda site to a high of 16.6% (51/307) at the Tanzania site (Table 1). Viraemia (HIV RNA >50 copies/mL at the most recent visit) was observed in 19.3% (n-396) participants and persistent viraemia (HIV RNA >50 copies/mL at the two consecutive most recent visits) observed in 7·8% (n = 160) of participants. Of the participants with persistent viraemia, only 57.5% (92/160) had confirmed virologic failure, i.e. HIV RNA >1000 copies/mL at two consecutive visits (Fig 3).

Predictors of virologic failure, viraemia and persistent viraemia

Results of the unadjusted and site adjusted analyses are shown in Tables 2 and 3. In the fully adjusted model, factors associated with increased risk of virologic failure at the most recent visit (Table 2) included being a participant at a site other than the Ugandan site, (SRV-Kenya aRR 2.6, 95%CI 1.40–4.91; Kisumu-Kenya aRR 2.2, 95%CI1.12–4.51; Tanzania aRR 4·3, 95% CI 2·29–8.21; and Nigeria aRR 3.3, 95%CI 1.68–6.52); being on 2nd line ART (aRR 1.28, 95% CI 1. 8–2.66); a history of fever in the past week (aRR 3.7, 95% CI 1·69–8.05), and missing any day of ART dosing/adherence (aRR 1·8, 95% CI 1.27–2.57). The factors that were associated with decreased risk for virologic failure included having a current CD4 count ≥ 500 cells/mm^3 (aRR 0·30, 95%CI, 0.23–0.49); older age (aRR 0·4, 95%CI 0·22–0·0.84); and high BMI (aRR 0·7, 95% CI 0·56–0·94).

Viraemia and persistent viraemia had similar risk factors as those identified for virologic failure, including being on 2nd line ART, being a participant at a site other than the Ugandan site, and current CD4 count < 500 cells/mm^3 (Table 3). Similar to the findings for virologic failure, adherence and history of fever in the past week increased the risk of viraemia but were not significantly associated with persistent viraemia.

In contrast to the findings for virologic failure, unemployment was protective for viraemia at the most recent visit and persistent viraemia (Table 3). Older participants were less likely to have persistent viraemia (aRR 0·5, 95% CI 0·28–0·85), while being married (aRR 0·7, 95% CI 0·53–0·93) was only protective for persistent viraemia (Table 2).

Discussion

Our study evaluated the prevalence of virologic failure and factors associated with virologic failure in a large African HIV cohort receiving ART based on the WHO's public health approach. Our findings showed that viraemia at the most recent visit occurred commonly, while persistent viraemia and virologic failure occurred less frequently.

Our findings further demonstrate that the site one attended for their ART care, the current CD4 count, and the ART regimen type were consistently associated with adverse virologic outcomes irrespective of the specific definition used. Other factors like low BMI, fever in the past week, and adherence were only associated with single measurement viraemia and virologic failure but not persistent viraemia. Younger age was only associated with persistent viraemia and virologic failure but not viraemia.

Our findings are significant in three important ways: first, viraemia as used in this analysis represents the definition of viral non-suppression (plasma HIV RNA > 50 copies/mL) as used in the high-income countries [24, 25] while virologic failure represents the definition of viral non-suppression (plasma HIV RNA > 1000 copies/mL) used by the WHO Public health

Table 1. Socio-demographic and clinical characteristics of 2054 HIV infected AFRICOS-participants by viral load category at the most recent visit.

Level	Total on ART $\geq$ 6 months (N = 2054)	Viral Load category (copies/mL)		p-value$^\infty$
		Viral Load <1000 (n = 1870)	Viral Load > = 1000 (n = 184)	
AFRICOS Site				
Uganda	352 (17.1%)	340 (18.2%)	12 (6.5%)	<0.001
SRV,Kenya	820 (39.9%)	751 (40.2%)	69 (37.5%)	
Kisumu, Kenya	365 (17.8%)	341 (18.2%)	24 (13.0%)	
Tanzania	307 (14.9%)	256 (13.7%)	51 (27.7%)	
Nigeria	210 (10.2%)	182 (9.7%)	28 (15.2%)	
Age in Years				
18–24	72 (3.5%)	58 (3.1%)	14 (7.6%)	<0.001
25–39	739 (36.0%)	657 (35.1%)	82 (44.6%)	
40–49	791 (38.5%)	729 (39.0%)	62 (33.7%)	
> = 50	452 (22.0%)	426 (22.8%)	26 (14.1%)	
Participant's Gender				
Male	874 (42.6%)	793 (42.4%)	81 (44.0%)	0.67
Female	1180 (57.4%)	1077 (57.6%)	103 (56.0%)	
Marital Status				
Not Married	831 (40.5%)	745 (39.8%)	86 (46.7%)	0.072
Married	1220 (59.4%)	1122 (60.0%)	98 (53.3%)	
Unknown	3 (0.1%)	3 (0.2%)	0 (0.0%)	
Highest Education Level				
None or some primary	694 (33.8%)	648 (34.7%)	46 (25.0%)	0.027
Some secondary	789 (38.4%)	711 (38.0%)	78 (42.4%)	
Post-Secondary	568 (27.7%)	508 (27.2%)	60 (32.6%)	
Missing	3 (0.1%)	3 (0.2%)	0 (0.0%)	
Current Employment Status				
Yes	1216 (59.2%)	1089 (58.2%)	127 (69.0%)	0.005
No	835 (40.7%)	778 (41.6%)	57 (31.0%)	
Missing	3 (0.1%)	3 (0.2%)	0 (0.0%)	
BMI Category (kg/m^2)				
<18.5	193 (9.4%)	174 (9.3%)	19 (10.3%)	0.89
18.5-<25	1277 (62.2%)	1163 (62.2%)	114 (62.0%)	
> = 25	584 (28.4%)	533 (28.5%)	51 (27.7%)	
Duration on ART (Years)				
0.5-<2	560 (27.3%)	503 (26.9%)	57 (31.0%)	0.33
2-<5	578 (28.1%)	524 (28.0%)	54 (29.3%)	
> = 5	916 (44.6%)	843 (45.1%)	73 (39.7%)	
Current CD4 Count (cells/mm^3)				
<200	204 (9.9%)	135 (7.2%)	69 (37.5%)	<0.001
200–349	395 (19.2%)	354 (18.9%)	41 (22.3%)	
350–499	501 (24.4%)	465 (24.9%)	36 (19.6%)	
500+	954 (46.4%)	916 (49.0%)	38 (20.7%)	
ART Regiment				
1st Line	1832 (89.2%)	1688 (90.3%)	144 (78.3%)	<0.001
2nd Line	215 (10.5%)	178 (9.5%)	37 (20.1%)	
Other	7 (0.3%)	4 (0.2%)	3 (1.6%)	
Adherence (#days missed)				

(*Continued*)

Table 1. (Continued)

Level	Total on ART ≥ 6 months (N = 2054)	Viral Load category (copies/mL)		p-value[∞]
		Viral Load <1000 (n = 1870)	Viral Load > = 1000 (n = 184)	
None	1775 (86.4%)	1635 (87.4%)	140 (76.1%)	<0.001
Any	275 (13.4%)	232 (12.4%)	43 (23.4%)	
Missing	4 (0.2%)	3 (0.2%)	1 (0.5%)	
Fever within the past week				
No	2033 (99.0%)	1856 (99.3%)	177 (96.2%)	<0.001
Yes	21 (1.0%)	14 (0.7%)	7 (3.8%)	

[∞]p-value in this table indicates if the variables in question are significantly different without necessarily indicating the direction of the difference. P-value <0.005 indicates statistical significance.

approach for low and middle income countries [26]. As such the rate of viral suppression observed will depend on the threshold of viral suppression used. Second, this analysis indicates that only 57.5% of participants with persistent viraemia (plasma HIV RNA > 50 copies/mL at two consecutive visits) will also have confirmed virologic failure, highlighting a need for


Fig 3. Overlap of participants with different thresholds of viraemia.

Table 2. Unadjusted and adjusted factors associated with virologic failure (Viral load≥1000 copies/ml).

Characteristics	Unadjusted		Site adjusted		Multivariate	
	RR	95% CI	RR	95% CI	RR	95% CI
HIV Program						
Uganda	1		-	-	1	
SRV, Kenya	2.5	1.35–4.50	-	-	2.6	1.40–4.91
Kisumu, Kenya	1.9	0.98–3.80	-	-	2.2	1.12–4.51
Tanzania	4.9	2.65–8.97	-	-	4.3	2.29–8.21
Nigeria	3.9	2.03–7.52	-	-	3.3	1.68–6.52
Age at most recent visit (years)						
≤24	1		1		1	
25–39	0.6	0.34–0.95	0.7	0.40–1.14	0.9	0.48–1.61
40–49	0.4	0.24–0.68	0.5	0.28–0.81	0.6	0.32–1.11
≥ 50	0.3	0.16–0.54	0.3	0.19–0.65	0.4	0.22–0.84
Gender						
Male	1		1			
Female	0.9	0.71–1.24	0.9	0.70–1.21	-	-
Marital Status					-	-
Not Married	1		1			
Married	0.8	0.59–1.02	0.8	0.63–1.09	-	-
Education level					-	-
None	1		1		-	-
Primary	1.5	1.05–2.12	1.1	0.76–1.59	-	-
Secondary School or above	1.6	1.10–2.30	1.0	0.69–1.57	-	-
Employment status						
Employed	1		1		-	
Unemployed	0.6	0.48–0.88	0.7	0.45–1.09	-	-
Body Mass Index (kg/m2)						
<18.5	1		1		1	
18.5 to 24.99	0.9	0.57–1.44	0.76	0.48–1.21	0.7	0.56–0.94
>25	0.9	0.54–1.46	0.64	0.38–1.06	0.7	0.50–0.90
CD4 at most recent visit (cells/mm^3)						
500 plus	1		1		1	
Less 200	8.5	5.9–12.1	7.6	5.3–10.9	6.9	4.7–10.2
200–349	2.8	1.9–4.3	2.7	1.8–4.0	2.5	1.6–3.8
350–499	1.8	1.1–2.7	1.7	1.1–2.6	1.7	1.1 2.6
Less than 500	1		1		1	
At least 500	0.3	0.21–0.42	0.3	0.22–0.45	0.3	0.23–0.49
Duration on ART (Years)						
Less than 2 years	1		1		-	-
2–<5	0.9	0.64–1.31	0.9	0.63–1.28	-	-
≥5 years	0.8	0.56–1.09	0.7	0.52–1.00	-	-
ART regimen type						
First line, NNRTI-based	1		1		1	
Second line, PI-based	2.2	1.57–3.05	2.0	1.47–2.87	1.8	1.28–2.66
Other	5.4	2.28–13.01	4.8	1.99–11.37	3.8	1.18–11.98
History of fever						
No	1		1		1	
Yes	3.8	2.06–7.12	4.1	2.33–7.15	3.7	1.69–8.05

(*Continued*)

Table 2. (Continued)

Characteristics	Unadjusted		Site adjusted		Multivariate	
	RR	95% CI	RR	95% CI	RR	95% CI
Adherence (# days missed)						
None	1		1		1	
Any days	2.0	1.44–2.72	2.0	1.40–2.73	1.8	1.27–2.57
Current Alcohol, & Drug Use						
No	1		1		-	-
Yes	1.2	0.64–2.27	1.1	0.58–2.08	-	-

https://doi.org/10.1371/journal.pone.0211344.t002

reviewing the WHO's threshold for viral suppression for the LMICs. Last, the findings demonstrate that ART programs in the regions are moving at different paces towards the 3rd UNAIDS 90 target and are not homogenous. This may be attributed to the different levels of quality of care that the programs have or the nature of the HIV epidemic in the different regions. Similar variation in the prevalence of virologic failure by geographic location has been reported before in other settings [27, 28]. Program level differences, for example unique site level processes, cultural differences or other factors such as variations in policies and their implementation [29], might explain some of these observations. It is also possible that these differences may be a reflection of the variation in the predominant HIV subtypes circulating in the participating sites. In Uganda and Kenya the predominant HIV subtypes are D and A, while in Tanzania it is subtype C and A, and in Nigeria subtype G and CRF02_AG predominate [30]. Whereas some published literature found an association between HIV subtype and treatment outcomes [31, 32], other studies have found no such association [33, 34]. In general, studies have found better ART response for HIV non-B compared to B subtypes [31], although a 2014 study in Spain found a lower virologic response on ART for HIV subtypes F compared to B subtypes [35].

We also found that younger age was significantly associated with virologic failure but not viraemia. Whereas some published studies have found that socio-demographic factors like age are associated with virologic suppression [36–39], other studies have found no such association [40, 41]. In general, younger age is usually associated with inadequate adherence to ART [42, 43], due to a number of unique behavioural and psychosocial factors like anxiety, stigma, lack of disclosure and low social economic status. This finding highlights the value of focusing on the special needs of young HIV-infected patients if we are to achieve the UNAIDS third 90 target.

Last, being on a second-line ART regimen was significantly associated with risk of virologic failure, independent of adherence. This is in line with findings reported by previous studies that have shown being on second line therapy is associated with viraemia and virologic failure [44]. Patients who are usually on second line therapy are those who have already failed on an earlier regimen. Although poor adherence on first line therapy usually predicts poor adherence on second therapy [45], the observed association between 2nd line therapy and virologic failure in this study appears to be independent of adherence or other measured factors like the current CD4 count, BMI or clinical site.

The authors recognize four major limitations of the analysis. First, the cross sectional nature of the analysis does not allow for causal inference or calculations of rates of failure. Second, these analyses do not include underlying HIV drug resistance that could be a driver of virologic failure. There is variability in the rates of baseline/pre-treatment HIVDR resistance in the literature. For example, while some reports indicate low rates of transmitted HIVDR [46], the

Table 3. Unadjusted and adjusted factors associated with viraemia.

Characteristics	Viraemia (Viral Load > 50copies/mL)				Persistent Viraemia (Viral Load > 50copies/mL at 2 consecutive visits)			
	Unadjusted		Multivariate		Unadjusted		Multivariate¶	
	RR	95% CI	RR	95% CI	RR	95% CI	RR	95% CI
HIV Program								
Uganda	1		1		1		1	
SRV, Kenya	2.0	1.33–2.99	1.6	1.04–2.59	3.1	1.50–6.46	2.3	1.15–4.68
Kisumu, Kenya	2.1	1.33–3.23	1.7	1.01–2.75	2.7	1.25–6.01	2.9	1.34–6.15
Tanzania	5.9	4.00–8.73	4.5	2.81–7.13	7.6	3.66–15.75	4.9	2.36–10.13
Nigeria	3.7	2.43–5.74	3.7	2.43–5.72	5.8	2.69–12.40	4.5	2.20–9.35
Age at most recent visit (Years)								
≤24	1		-	-	1		1	
25–39	0.6	0.44–0.90	-	-	0.3	0.21–0.54	0.7	0.44–1.25
40–49	0.5	0.38–0.78	-	-	0.2	0.15–0.41	0.5	0.32–0.96
≥ 50	0.5	0.32–0.70	-	-	0.2	0.14–0.41	0.5	0.28–0.85
Gender								
Male	1		-		1		-	
Female	0.87	0.72–1.03	-	-	1.0	0.73–1.32	-	-
Current Marital Status								
Not Married	1				1		1	
Married	0.77	0.65–0.92	-	-	0.6	0.46–0.82	0.7	0.54–0.97
Education level								
None	1		-	-	1		-	-
Primary	1.54	1.23–1.93	-	-	1.4	0.96–2.04	-	-
> = Secondary School	1.53	1.20–1.95	-	-	1.8	1.20–2.57	-	-
Employment status								
Employed	1		1		1		-	
Unemployed	0.62	0.51–0.75	0.7	0.54–0.93	0.6	0.43–0.81	0.6	0.38–1.00
Body Mass Index (kg/m2)								
<18.5	1		1		1		-	
18.5 to 24.99	0.80	0.60–1.04	0.7	0.56–0.94	0.8	0.50–1.24	-	-
≥25	0.77	0.57–1.04	0.7	0.50–0.90	0.7	0.43–1.18	-	-
CD4 at most recent visit (cells/mm³)								
Less than 500	1		1		1			
At least 500	0.6	0.47–0.68	0.63	0.52–0.765	0.3	0.24–0.48	0.4	0.28–0.58
Duration on ART (Years)								
Less than 2 years	1		-	-	1		-	-
2–<5	1.0	0.79–1.27	-	-	0.8	0.54–1.27	-	-
≥5 years	0.97	0.78–1.20	-	-	1.0	0.68–1.45	-	-
ART regimen type								
1st Line	1		1		1		1	
2nd Line	2.3	1.91–2.82	2.1	1.70–2.50	3.9	2.93–5.28	3.0	2.26–4.10
Other	2.5	1.08–6.03	1.5	0.82–2.59	4.9	1.57–15.54	3.8	1.40–0.47
History of fever								
No	1		1		1		-	
Yes	2.2	1.37–3.73	1.7	1.14–2.68	2.5	1.03–5.97	-	-
Adherence (# days missed)								
None	1		1		1		-	

(Continued)

Table 3. (Continued)

Characteristics	Viraemia (Viral Load > 50copies/mL)				Persistent Viraemia (Viral Load > 50copies/mL at 2 consecutive visits)			
	Unadjusted		Multivariate		Unadjusted		Multivariate[¶]	
	RR	95% CI	RR	95% CI	RR	95% CI	RR	95% CI
Any days	1.4	1.12–1.76	1.3	1.03–1.60	1.4	1.00–2.10	-	-
Current Alcohol, & Drug Use								
No	1		-	-	1		-	-
Yes	1.4	0.96–2.01	-	-	1.7	0.96–3.00	-	-

[¶]Backwards selection with 0.05 significance level was used to select variables for inclusion in the final multivariable models

https://doi.org/10.1371/journal.pone.0211344.t003

WHO HIV drug resistance report 2017 reported very high rates of up to 15.4%, in East Africa, 7.2% in West Africa, and 11% in Southern Africa. Future analysis of data from our cohort will evaluate the contribution of HIV drug resistance to virologic failure. Third, adherence data was based on self-report, which may be impacted by recall and social desirability bias. Last, the finding that a sizable proportion of participants with persistent viraemia did not have virologic failure confirmed as per WHO guidelines, although not a major objective of the current analysis, is potentially significant as it suggests a need for a review of the current WHO viral suppression threshold for LMICs in order to achieve the 3rd of the UNAIDS 90-90-90 targets. We are aware of randomised trials like the SESOTHO clinical trial [47] that are examining the subject of the WHO threshold for viral suppression for the LMICs that will include data on clinical outcomes for patients with persistent viraemia, which will complement the current analysis. Despite these limitations we would like to highlight two major strengths of our study: 1) all participants were monitored and received standardized laboratory and clinical evaluations allowing for accurate measurements, 2) a constant and adequate sample size for the majority of variables considered for this analysis, strengthening the robustness of the analysis results. Therefore, it is likely that our results are a reflection of the ART programs in these countries.

Conclusions

In conclusion, this multi-center analysis demonstrates that HIV-infected patients established on ART for more than six months in the African setting frequently experienced viraemia while continuing to be on ART. We have shown that clinical care sites home to AFRICOS are different and that further analyses will be required to elucidate on the unique features of these sites. We have also demonstrated that low BMI, low CD4 count, and history of fever in the past week remain important predictors of virologic failure that should be used as a marker for intensified adherence counselling especially in the absence of reliable or readily available viral load monitoring. Finally, younger age and single marital status are associated with virologic failure, which has implications for programmatic treatment monitoring practices.

Supporting information

S1 PDF. African Cohort Study blank CRFs.
(PDF)

S2 PDF. African Cohort Study blank subject questionnaire.
(PDF)

Acknowledgments

Author Contributions

Conceptualization: Francis Kiweewa, Trevor A. Crowell, Monica Millard, Merlin L. Robb, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Data curation: Francis Kiweewa, Allahna Esber, Ezra Musingye, Trevor A. Crowell, Jonah Maswai, John Owuoth, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Formal analysis: Francis Kiweewa, Allahna Esber, Ezra Musingye, Domonique Reed, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Funding acquisition: Monica Millard, Merlin L. Robb, Julie A. Ake, Christina S. Polyak.

Investigation: Francis Kiweewa, Fatim Cham, Leigh Anne Eller, Jonah Maswai, John Owuoth, Emmanuel Bahemana, Samoel Khamadi, Hannah Kibuuka.

Methodology: Francis Kiweewa, Michael Semwogerere, Alice Nambuya, Cate Kafeero, Allan Tindikahwa, Monica Millard, Babajide Keshinro, Yakubu Adamu, Jonah Maswai, John Owuoth, Lucas Maganga, Samoel Khamadi, Merlin L. Robb, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Project administration: Francis Kiweewa, Julie A. Ake.

Resources: Monica Millard, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Supervision: Francis Kiweewa, Michael Semwogerere, Alice Nambuya, Allan Tindikahwa, Leigh Anne Eller, Monica Millard, Huub C. Gelderblom, Babajide Keshinro, Yakubu Adamu, Jonah Maswai, John Owuoth, Valentine Chepkorir Sing'oei, Lucas Maganga, Emmanuel Bahemana, Samoel Khamadi, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Validation: Francis Kiweewa, Allahna Esber, Trevor A. Crowell, Michael Semwogerere, Rosemary Namagembe, Allan Tindikahwa, Babajide Keshinro, Yakubu Adamu, Valentine Chepkorir Sing'oei, Emmanuel Bahemana, Merlin L. Robb, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

Writing – original draft: Francis Kiweewa.

Writing – review & editing: Francis Kiweewa, Allahna Esber, Ezra Musingye, Domonique Reed, Trevor A. Crowell, Fatim Cham, Michael Semwogerere, Rosemary Namagembe, Alice Nambuya, Cate Kafeero, Allan Tindikahwa, Leigh Anne Eller, Monica Millard, Huub C. Gelderblom, Babajide Keshinro, Yakubu Adamu, Jonah Maswai, John Owuoth, Valentine Chepkorir Sing'oei, Lucas Maganga, Emmanuel Bahemana, Samoel Khamadi, Merlin L. Robb, Julie A. Ake, Christina S. Polyak, Hannah Kibuuka.

References

1. UNAIDS, Joint United Nations Programme on HIV/AIDS: *90-90-90. An ambitious treatment target to help end the AIDS epidemic.* Geneva, Switzerland, UNAIDS, Joint United Nations Programme on HIV/AIDS, 2014 Oct. 40 p, 2014.

2. Abrams E.J. and Strasser S., 90-90-90—Charting a steady course to end the paediatric HIV epidemic. J Int AIDS Soc, 2015. 18(Suppl 6): p. 20296. https://doi.org/10.7448/IAS.18.7.20296 PMID: 26639119

3. WHO, 2016 Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. *Recommendations for a public health approach*— Second edition. World Health Organization, 2016.

4. UNAIDS, Ending AIDS: Progress towards the 90–90–90 targets. The Joint United Nations Programme on HIV/AID Global AIDS Update 2017. UNAIDS, 2017.

5. UNAIDS, "15 BY 15" A GLOBAL TARGET. UNAIDS, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. UNAIDS, Joint United Nations Programme on HIV/AIDS (UNAIDS), Geneva, Switzerland. 2015.

6. Skarbinski J., et al., Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med, 2015. 175(4): p. 588–96. https://doi.org/10.1001/jamainternmed.2014.8180 PMID: 25706928

7. Barth R.E., et al., Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis, 2010. 10(3): p. 155–66. https://doi.org/10.1016/S1473-3099(09)70328-7 PMID: 20185094

8. Aghokeng A.F., et al., Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia. Clin Infect Dis, 2014. 58(1): p. 99–109. https://doi.org/10.1093/cid/cit627 PMID: 24076968

9. Hamers R.L., et al., Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis, 2012. 54(11): p. 1660–9. https://doi.org/10.1093/cid/cis254 PMID: 22474222

10. Gupta R.K., et al., Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet, 2012. 380(9849): p. 1250–8. https://doi.org/10.1016/S0140-6736(12)61038-1 PMID: 22828485

11. Bulage L., et al., Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014-July 2015. BMC Infect Dis, 2017. 17(1): p. 326. https://doi.org/10.1186/s12879-017-2428-3 PMID: 28468608

12. Huong D.T., et al., Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam. Int J STD AIDS, 2011. 22(11): p. 659–64. https://doi.org/10.1258/ijsa.2011.010515 PMID: 22096052

13. Jobanputra K., et al., Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One, 2015. 10(2): p. e0116144. https://doi.org/10.1371/journal.pone.0116144 PMID: 25695494

14. d'Arminio Monforte A., et al., Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS, 2000. 14(5): p. 499–507. PMID: 10780712

15. Mocroft A., et al., Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre. AIDS, 2001. 15(2): p. 185–94. PMID: 11216926

16. Parczewski M., et al., Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. J Int AIDS Soc, 2017. 20(1): p. 21847. https://doi.org/10.7448/IAS.20.1.21847 PMID: 28715160

17. Duber H.C., et al., Evaluating facility-based antiretroviral therapy programme effectiveness: a pilot study comparing viral load suppression and retention rates. Trop Med Int Health, 2016. 21(6): p. 750–8. https://doi.org/10.1111/tmi.12694 PMID: 26996396

18. Fokam J., et al., Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaounde-Cameroon. PLoS One, 2017. 12(11): p. e0187566. https://doi.org/10.1371/journal.pone.0187566 PMID: 29112991

19. Denoeud-Ndam L., et al., Predictive factors of plasma HIV suppression during pregnancy: a prospective cohort study in Benin. PLoS One, 2013. 8(3): p. e59446. https://doi.org/10.1371/journal.pone.0059446 PMID: 23555035

20. Ake J.A., et al., Noninfectious Comorbidity in the African Cohort Study (AFRICOS). Clin Infect Dis, 2018.

21. Tanner Z., et al., Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infect Dis, 2016. 16(1): p. 590. https://doi.org/10.1186/s12879-016-1926-z PMID: 27769246

22. Snippenburg W., et al., Factors associated with time to achieve an undetectable HIV RNA viral load after start of antiretroviral treatment in HIV-1-infected pregnant women. J Virus Erad, 2017. 3(1): p. 34–39. PMID: 28275456

23. European Collaborative, S., et al., Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis, 2007. 44(12): p. 1647–56. https://doi.org/10.1086/518284 PMID: 17516411

24. Asboe D., et al., British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Med, 2012. 13(1): p. 1–44. https://doi.org/10.1111/j.1468-1293.2011.00971.x PMID: 22171742

25. Gunthard H.F., et al., Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA, 2016. 316(2): p. 191–210. https://doi.org/10.1001/jama.2016.8900 PMID: 27404187

26. WHO, 2013 WHO Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, in Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, n. edition., Editor. 2016: Geneva.

27. Elvstam O., et al., Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. PLoS One, 2017. 12(7): p. e0180761. https://doi.org/10.1371/journal.pone.0180761 PMID: 28683128

28. Leng X., et al., HIV virological failure and drug resistance among injecting drug users receiving first-line ART in China. BMJ Open, 2014. 4(10): p. e005886. https://doi.org/10.1136/bmjopen-2014-005886 PMID: 25319999

29. Church K., et al., A comparative analysis of national HIV policies in six African countries with generalized epidemics. Bull World Health Organ, 2015. 93(7): p. 457–67. https://doi.org/10.2471/BLT.14.147215 PMID: 26170503

30. Lihana R.W., et al., Update on HIV-1 diversity in Africa: a decade in review. AIDS Rev, 2012. 14(2): p. 83–100. PMID: 22627605

31. Scherrer A.U., et al., Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. Clin Infect Dis, 2011. 53(11): p. 1143–52. https://doi.org/10.1093/cid/cir669 PMID: 21998284

32. Paraskevis D., et al., Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals. AIDS Res Hum Retroviruses, 2013. 29(3): p. 461–9. https://doi.org/10.1089/AID.2012.0143 PMID: 23034083

33. Pillay D., et al., Impact of human immunodeficiency virus type 1 subtypes on virologic response and emergence of drug resistance among children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 trial. J Infect Dis, 2002. 186(5): p. 617–25. https://doi.org/10.1086/342680 PMID: 12195348

34. Geretti A.M., et al., Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy. Clin Infect Dis, 2009. 48(9): p. 1296–305. https://doi.org/10.1086/598502 PMID: 19331585

35. Pernas B., et al., High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS, 2014. 28(12): p. 1837–40. https://doi.org/10.1097/QAD.0000000000000326 PMID: 24871456

36. O'Connor J., et al., Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV, 2017. 4(7): p. e295–e302. https://doi.org/10. 1016/S2352-3018(17)30053-X PMID: 28479492

37. DeJesus E., et al., Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet, 2012. 379(9835): p. 2429–38. https://doi.org/10.1016/S0140-6736(12)60918-0 PMID: 22748590

38. Lodi S., et al., Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV, 2015. 2(8): p. e335–43. https://doi.org/10.1016/S2352-3018(15)00108-3 PMID: 26423376

39. Mujugira A., et al., Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships. AIDS Res Hum Retroviruses, 2016. 32(2): p. 148–54. https://doi.org/10.1089/AID.2015.0296 PMID: 26670218

40. Arnedo M., et al., Monitoring HIV viral load in resource limited settings: still a matter of debate? PLoS One, 2012. 7(12): p. e47391. https://doi.org/10.1371/journal.pone.0047391 PMID: 23236346

41. Crawford K.W., et al., Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses. HIV Med, 2015. 16(2): p. 95–104. https://doi.org/10.1111/ hiv.12177 PMID: 25124078

42. Kim S.H., et al., Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS, 2014. 28(13): p. 1945–56. https://doi.org/10.1097/QAD.0000000000000316 PMID: 24845154

43. Semvua S.K., et al., Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. PLoS One, 2017. 12(12): p. e0189460. https://doi.org/10.1371/journal.pone. 0189460 PMID: 29252984

44. Labhardt N.D., et al., When patients fail UNAIDS' last 90—the "failure cascade" beyond 90-90-90 in rural Lesotho, Southern Africa: a prospective cohort study. J Int AIDS Soc, 2017. 20(1): p. 21803. https://doi.org/10.7448/IAS.20.1.21803 PMID: 28777506

45. Ramadhani H.O., et al., Association of first-line and second-line antiretroviral therapy adherence. Open Forum Infect Dis, 2014. 1(2): p. ofu079.

46. Reynolds S.J., et al., Low Rates of Transmitted Drug Resistance Among Newly Identified HIV-1 Seroconverters in Rural Rakai, Uganda. AIDS Res Hum Retroviruses, 2017. 33(5): p. 448–451. https://doi. org/10.1089/AID.2015.0370 PMID: 27798967

47. Amstutz A., et al., SESOTHO trial ("Switch Either near Suppression Or THOusand")—switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa. BMC Infect Dis, 2018. 18(1): p. 76. https://doi.org/10.1186/s12879-018-2979-y PMID: 29433430